Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

CPRX
Catalyst Pharmaceutical Inc.
stock NASDAQ

At Close
Jul 9, 2025 3:59:58 PM EDT
21.62USD+4.193%(+0.87)1,480,216
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 9, 2025 9:27:30 AM EDT
21.00USD+1.205%(+0.25)1,316
After-hours
Jul 9, 2025 4:40:30 PM EDT
21.66USD+0.204%(+0.04)23,147
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsMore
open chart   
open chart   
Market Cap
2.64B
CEO
Patrick McEnany
Headquarters
Coral Gables, Florida, USA
Industry
Biotechnology
Next Earnings
Aug 6, 2025 (27d)
Related
BMRNACORABTJNJPFESRPTARDMXLV
CPRX Stats
Avg. Vol. 10 Day
1,314,976
Avg. Vol. 30 Day
1,319,603
Employees
21
Market Cap
2,638,322,538
Shares Out.
121,975,152
On/Off Exchange
58%/42%
6 Month Beta
0.81
1 Year Beta
0.93
2 Year Beta
0.99
3 Year Beta
1.01
52 Week Low
15.19
52 Week High
26.58
SMA50
23.65
SMA200
22.39
1 Week
+0.84%
1 Month
-16.29%
3 Month
-4.88%
6 Month
-1.32%
1 Year
+38.57%
2 Year
+71.80%
5 Year
+330.88%
Profile
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso

CPRX Stock Summary

Catalyst Pharmaceutical Inc. (NASDAQ:CPRX) stock price today is $21.62, and today's volume is 1,480,216. CPRX is up 4.193% today. The 30 day average volume is 1,319,603. CPRX market cap is 2.64B with 121,975,152 shares outstanding.



Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC